evaluate the digital health company amwell on ozempic / semaglutide popularity among privately insured may worsen disparities ACTIVE LEARNING TEMPLATE: Ozempic (Semaglutide)

In the ATTAIN1 trial, patients without diabetes taking the highest dose of Foundayo lost an average of 11-12% of their body weight over 72 weeks

De novo variants in the KMT2A (MLL) gene causing atypical Wiedemann-Steiner syndrome in two unrelated individuals identified by clinical exome sequencing

Last updated June 3, 2026 Editorial policy From Weight Loss Clinics to Addiction Labs The trajectory of GLP-1 receptor agonists has taken a turn that few in the pharmaceutical world predicted

Rizzo III Researchers obtained electronic health record data from adults who attended Massachusetts Eye and Ear for a presumed neuro-ophthalmology indication from Dec